Latest B-cell chronic lymphocytic leukemia Stories
-Standard treatment for chronic leukemia is too harsh for many older patients. -Early clinical trials testing indicates that these patients respond well to the experimental drug ibrutinib. -This agent merits further testing as a first-line therapy for older chronic-leukemia patients. The experimental drug ibrutinib (PCI-32765) shows great promise for the treatment of older patients with chronic lymphocytic leukemia (CLL), according to interim findings from a clinical trial. The phase...
SUNNYVALE, Calif., May 17, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib (formerly, PCI-32765) have been selected for oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012 in Chicago, IL. The update on data presented for the first time will specifically include: 1) safety and efficacy data from the phase II CLL single agent...
THOUSAND OAKS, Calif., May 16, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study. Blinatumomab is the first of a new class of agents called bi-specific T cell engagers (BiTE®) antibodies, designed to harness...
SUNNYVALE, Calif., May 10, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal third quarter ended March 31, 2012. Financial Results for Third Quarter Ended March 31, 2012 The non-GAAP (Generally Accepted Accounting Principles) net loss reported for the fiscal quarter ended March 31, 2012 was $9.3 million, or $0.14 loss per share. This compares with a non-GAAP net loss of $7.4 million, or $0.12 loss per...
Results open up field of T cell gene therapy for use in other diseases HIV patients treated with genetically modified T cells remain healthy up to 11 years after initial therapy, researchers from the Perelman School of Medicine at the University of Pennsylvania report in the new issue of Science Translational Medicine. The results provide a framework for the use of this type of gene therapy as a powerful weapon in the treatment of HIV, cancer, and a wide variety of other diseases. "We...
WHITE PLAINS, N.Y., April 19, 2012 /PRNewswire-USNewswire/ -- The Leukemia & Lymphoma Society (LLS) salutes Carl June, M.D., of University of Pennsylvania School of Medicine, and the members of his team, for the latest recognition of their groundbreaking advances in immunotherapy. Today the Clinical Research Forum announced Dr. June's lab as among its Top 10 Clinical Research Achievement Awards. The awards recognize studies, all published within the last two years, that represent...
Eleven Bay Area professionals kick-off spirited 10-week competition to raise funds for blood cancer research. SAN FRANCISCO, March 29, 2012 /PRNewswire-USNewswire/ -- The Greater San Francisco Bay Area Chapter of The Leukemia & Lymphoma Society (LLS) launched its 22nd annual Man & Woman of the Year fundraising campaign with a heartwarming reception at the Mark Hopkins San Francisco this evening. Highlighting the festivities was the reveal of the 11 Bay Area...
SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a Phase 1 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in pediatric patients with emphasis on leukemia, lymphoma and sarcoma cancers. These three cancers represent approximately 50% of all cancers that occur in the pediatric population. Patients with advanced cancers who have failed current therapy will be...
SUNNYVALE, Calif., Feb. 9, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal second quarter ended December 31, 2011. Financial Results for Second Quarter Ended December 31, 2011 The non-GAAP (Generally Accepted Accounting Principles) net income reported for the fiscal quarter ended December 31, 2011 was $58.6 million, or $0.82 diluted earnings per share. This compares with a non-GAAP net loss of $6.1 million, or...
SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- TrovaGene, Inc. (Pink Sheets: TROV), a developer of trans-renal molecular diagnostics, today announced that it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia (CLL). The findings have been published in the Dec 22 issue of BLOOD, the journal of the...
